Haduvio Push Extended, but Trevi's Valuation Stretched

What happened

Trevi Therapeutics detailed plans to advance Haduvio across chronic cough indications, emphasizing upcoming trial starts and a cash runway extended into 2030 after a recent financing. The company aims to begin Phase 3 IPF chronic cough and Phase 2b RCC trials in 1H 2026 with a specialty commercial strategy. However, at $11.18 and a ~$1.4B market cap, the stock already prices in high Phase 3 success probabilities despite being a single-asset, pre-revenue biotech. Risks from potential FDA demands for larger trials, opioid-class labeling, and further dilutive equity raises remain underappreciated. The extended runway reduces near-term financing risk but does not alter the fundamental risk-reward skew; the stock is overvalued relative to its pre-pivotal stage and crowded ownership.

Implication

Investors should consider trimming positions into strength as the market already prices in optimistic assumptions. While the cash runway into 2030 provides flexibility, the stock's valuation (P/E negative, EV/EBITDA negative) reflects expectations of successful Phase 3 execution and commercial launch. However, post-gefapixant regulatory caution could demand larger, longer trials, increasing cost and delaying approval. Competitors like GSK's camlipixant may erode first-mover advantage. Maintain a cautious stance and revisit after End-of-Phase 2 FDA feedback and trial initiation clarity. If the stock falls to the attractive entry of $8.50, a position could be built, but until then, risk-reward is unfavorable.

Thesis delta

The prior thesis viewed Trevi as a speculative buy with binary catalyst potential, but the extended runway and positive trial data have been more than fully priced in. The new information reinforces the sell thesis: the extended runway removes immediate financing risk, but the valuation is stretched and the drug's commercial viability remains unproven. The thesis shifts from 'hold for catalysts' to 'sell on strength' as the risk-reward is now skewed to the downside.